231. Alpha-1-antitrypsin deficiency
83 clinical trials,   89 drugs   (DrugBank: 16 drugs),   35 drug target genes,   46 drug target pathways

Searched query = "Alpha-1-antitrypsin deficiency", "AATD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-014286-20-IE
(EUCTR)
21/12/201031/05/2010A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency - rAAV1-CB-hAAT in Patients with Alpha 1 Antitrypsin DeficiencyA Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency - rAAV1-CB-hAAT in Patients with Alpha 1 Antitrypsin Deficiency Alpha 1 antitrypsin deficiency.This is an inherited, genetic condition characterized by reduced serum levels of alpha-1 antitrypsin (AAT) which increases the risk of developing emphysema and liver disease
MedDRA version: 12.1;Level: PT;Classification code 10001806;Term: Alpha-1 anti-trypsin deficiency
Product Name: rAAV1-CB-hAAT
Product Code: rAAV1-CB-hAAT
Applied Genetic Technologies CorporationNULLNot RecruitingFemale: yes
Male: yes
9Phase 2Ireland
2NCT01054339
(ClinicalTrials.gov)
June 201021/1/2010Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin DeficiencyA Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha-1 Antitrypsin (rAAV1-CB-hAAT) in Patients With Alpha-1 Antitrypsin DeficiencyAlpha-1 Antitrypsin DeficiencyDrug: rAAV1-CB-hAATApplied Genetic Technologies CorpNational Heart, Lung, and Blood Institute (NHLBI)Completed18 Years75 YearsAll9Phase 2United States;Ireland
3NCT00430768
(ClinicalTrials.gov)
February 200631/1/2007Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) DeficiencyPreclinical & Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV1-CB-hAAT) Gene Vector to AAT-Deficient AdultsAlpha 1-Antitrypsin DeficiencyBiological: rAAV1-CB-hAATUniversity of Massachusetts, WorcesterNational Heart, Lung, and Blood Institute (NHLBI);Applied Genetic Technologies Corp;Alpha-1 Foundation;University of Florida;National Center for Research Resources (NCRR)Completed18 YearsN/AAll9Phase 1United States